Catalog No.
KDE43401
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
BMS-986015, IPH2102, CAS: 1000676-41-4
Background
Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC.
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets., PMID:38955423
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab., PMID:38185735
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy., PMID:38155060
Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition., PMID:35174079
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck., PMID:34667025
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies., PMID:32601377
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma., PMID:30828910
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome., PMID:30001986
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies., PMID:29707140
High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals., PMID:28723950
How to outsmart NK cell tolerance., PMID:26405590
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy., PMID:24701370
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies., PMID:24326534
For research use only. Not for human or drug use.
